Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxabact open-label extension in primary hyperoxaluria
2007-006187-30Phase 3Completed
- Sponsor
- OxThera AB
- Start
- Feb 2008
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of oxalobacter formigenes in Primary hyperoxaluria (PH) and hyperoxaluria, sponsored by OxThera AB. Primary endpoint: Safety. Started Feb 2008; status: completed.
02
Drugs
oxalobacter formigenes
03
Conditions
Primary hyperoxaluria (PH)hyperoxaluria
Beyond the preview
Go deeper on 2007-006187-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-006187-30.